Zhou, B.
Stueve, T. R.
Mihalakakos, E. A.
Miao, L.
Mullen, D.
Wang, Y.
Liu, Y.
Luo, J.
Tran, E.
Siegmund, K. D.
Lynch, S. K.
Ryan, A. L.
Offringa, I. A.
Borok, Z.
Marconett, C. N. http://orcid.org/0000-0002-8463-7126
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01 HL114094-01, R35 HL135747, HL 114959)
National Cancer Institute (P30 CA014089-43)
American Cancer Society (RSG-20-135- 01-RMC)
U.S. Department of Defense (W81XWH-21-1-0231)
Article History
Received: 13 May 2021
Accepted: 5 November 2021
First Online: 18 December 2021
Declarations
:
: Remnant human transplant lung was obtained from donors in compliance with protocols for the use of human source material in research under University of Southern California, Health Science Campus Institutional Review Board HS-07-00660. Donors were deceased and samples de-identified, and this study did not require ethics approval or consent to participate as it holds an “exempt” status from human subjects research, as pursuant to the National Institute of Health’s “Code of Federal Regulations, TITLE 45: PUBLIC WELFARE, Issued by the Department of Health and Human Services (HHS): PART 46- PROTECTION OF HUMAN SUBJECTS, subsection §46.104: Exempt research.
: Not applicable.
: The authors declare that they have no competing interests.